Get the Stockscreener App
7.15
8.68%
-0.68
After Hours:
7.24
0.09
+1.26%
Regenxbio Inc stock is traded at $7.15, with a volume of 1.05M.
It is down -8.68% in the last 24 hours and up +8.83% over the past month.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.
See More
Previous Close:
$7.83
Open:
$7.45
24h Volume:
1.05M
Relative Volume:
1.16
Market Cap:
$360.30M
Revenue:
$89.04M
Net Income/Loss:
$-241.08M
P/E Ratio:
-1.3593
EPS:
-5.26
Net Cash Flow:
$-194.72M
1W Performance:
-17.82%
1M Performance:
+8.83%
6M Performance:
-31.84%
1Y Performance:
-66.07%
1-Day Range:
$6.774
$7.46
1-Week Range:
$6.774
$8.65
52-Week Range:
$5.66
$21.57
Regenxbio Inc Stock (RGNX) Company Profile
Name
Regenxbio Inc
Sector
Industry
Phone
240-552-8181
Address
9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD
Compare RGNX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RGNX
Regenxbio Inc
|
7.15 | 360.30M | 89.04M | -241.08M | -194.72M | -5.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Regenxbio Inc Stock (RGNX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-11-25 | Downgrade | Goldman | Buy → Neutral |
| Feb-07-25 | Resumed | Raymond James | Outperform |
| Nov-15-24 | Resumed | Morgan Stanley | Overweight |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Jun-07-24 | Initiated | Goldman | Buy |
| Mar-11-24 | Initiated | H.C. Wainwright | Buy |
| Mar-08-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-06-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Feb-21-24 | Resumed | Raymond James | Outperform |
| Nov-01-23 | Initiated | Stifel | Buy |
| Jun-02-23 | Initiated | Robert W. Baird | Outperform |
| Jun-23-22 | Initiated | Berenberg | Buy |
| Dec-15-21 | Initiated | Wedbush | Neutral |
| Oct-19-21 | Resumed | Morgan Stanley | Overweight |
| Jan-06-21 | Upgrade | Raymond James | Outperform → Strong Buy |
| Dec-16-20 | Initiated | UBS | Buy |
| Jun-25-20 | Resumed | BofA/Merrill | Buy |
| May-13-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Aug-20-19 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Jun-18-19 | Reiterated | Chardan Capital Markets | Buy |
| Jun-14-19 | Resumed | Raymond James | Outperform |
| Jun-05-19 | Reiterated | Chardan Capital Markets | Buy |
| Feb-25-19 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-05-19 | Upgrade | Raymond James | Outperform → Strong Buy |
| Dec-17-18 | Reiterated | Chardan Capital Markets | Buy |
| Nov-08-18 | Reiterated | BofA/Merrill | Neutral |
| Aug-08-18 | Reiterated | Chardan Capital Markets | Buy |
| Jul-23-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jul-10-18 | Reiterated | Chardan Capital Markets | Buy |
| May-09-18 | Reiterated | Barclays | Overweight |
| Apr-09-18 | Reiterated | Chardan Capital Markets | Buy |
| Mar-12-18 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-13-18 | Initiated | Mizuho | Neutral |
| Nov-09-17 | Resumed | Morgan Stanley | Overweight |
View All
Regenxbio Inc Stock (RGNX) Latest News
Clear Street sets Regenxbio stock Buy rating, $50 target - Investing.com India
5 Reasons To Buy Regenxbio Right Now (NASDAQ:RGNX) - Seeking Alpha
REGENXBIO partners with Nippon Shinyaku for MPS therapies - MSN
Regenxbio’s Triple Threat: Partnered Programs, DMD Progress And In-House Manufacturing - insights.citeline.com
RegenXBio Positioned Favorably Amid Competitor Safety Concerns, Justifying Buy Rating - TipRanks
REGENXBIO’s DMD Gene Therapy RGX-202 Generates Microdystrophin Expression in Additional Patients Treated in Phase 1/2 Trial - CGTLive™
Regenxbio Rises After Duchenne Update And Sarepta Safety Scare - insights.citeline.com
Sarepta safety update on Elevidys boosts Regenxbio, hurts Solid Bio - MSN
Regenxbio’s RGX-202 continues to show promise in DMD - The Pharma Letter
Regenxbio’s DMD gene therapy drives 122.3% biomarker uptick in three-year-old - Clinical Trials Arena
Regenxbio stock target raised to $29 at Raymond James By Investing.com - Investing.com Canada
REGENXBIO reports promising gene therapy trial results By Investing.com - Investing.com South Africa
Baird maintains Regenxbio stock outperform rating, $39 target By Investing.com - Investing.com South Africa
Baird maintains Regenxbio stock outperform rating, $39 target - Investing.com
Regenxbio stock target raised to $29 at Raymond James - Investing.com India
Regenxbio up 4% following additional data on Duchenne gene therapy asset - MSN
Regenxbio Touts Positive Biomarker Data From Duchenne Muscular Dystrophy Gene Therapy Trial - Benzinga
Regenxbio Says New Data Support Potential Gene Therapy for Duchenne Muscular Dystrophy - MarketScreener
REGENXBIO reports promising gene therapy trial results - Investing.com India
REGENXBIO: New Interim Data Reinforces Potential Of RGX-202Quick Facts - Nasdaq
Breakthrough: REGENXBIO DMD Gene Therapy Achieves Unprecedented 122% Protein Expression - StockTitan
Regenxbio stock up, Solid Bio down post Sarepta update (RGNX) - Seeking Alpha
Regenxbio at UBS Virtual CNS Day: Gene Therapy Advancements - Investing.com
Regenxbio at UBS Virtual CNS Day: Gene Therapy Advancements By Investing.com - Investing.com Canada
H.C. Wainwright cuts Regenxbio stock target to $34, maintains buy By Investing.com - Investing.com Philippines
REGENXBIO Inc. (NASDAQ:RGNX) Is About To Turn The Corner - Yahoo Finance
H.C. Wainwright cuts Regenxbio stock target to $34, maintains buy - Investing.com India
Regenxbio completes its BLA filing for first potential gene therapy for MPS II - The Pharma Letter
REGENXBIO Earnings Call Highlights Strategic Progress - TipRanks
Earnings call transcript: Regenxbio Q4 2024 beats EPS forecast, stock surges - Investing.com Australia
Stifel maintains Buy on Regenxbio stock, $40 target By Investing.com - Investing.com South Africa
Stifel maintains Buy on Regenxbio stock, $40 target - Investing.com India
A Glimpse Into The Expert Outlook On Regenxbio Through 5 Analysts - Benzinga
Regenxbio Inc earnings beat by $0.12, revenue fell short of estimates - Investing.com Australia
Regenxbio Inc (RGNX) Q4 2024 Earnings Call Highlights: Strategic Advances and Financial Resilience - Yahoo Canada Finance
REGENXBIO Reports Progress in Gene Therapy Pipeline - TipRanks
Regenxbio Q4 License & Royalty Revenue USD 21.214 Million -March 13, 2025 at 05:37 pm EDT - Marketscreener.com
Regenxbio Inc (RGNX) Q4 2024 Earnings: EPS Beats Estimates at -$1.01, Revenue Misses at $21.2 Million - GuruFocus.com
Regenxbio (RGNX) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
Regenxbio: Q4 Earnings Snapshot - San Antonio Express-News
Regenxbio Inc reports results for the quarter ended December 31Earnings Summary - TradingView
REGENXBIO Earnings Results: $RGNX Reports Quarterly Earnings - Nasdaq
Regenxbio Inc Stock (RGNX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.05%
1.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):